Back to Search
Start Over
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
- Source :
- Cancers, Vol 12, Iss 2747, p 2747 (2020), Cancers, Volume 12, Issue 10
- Publication Year :
- 2020
- Publisher :
- MDPI AG, 2020.
-
Abstract
- With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). Analysis of minimal disseminated disease (MDD), available for 162 patients, showed that both SC/LH pattern (hazard ratio = 2.4) and MDD positivity (hazard ratio = 2.15) were significantly associated with risk of failure in multivariate analysis. Considering MDD and SC/LH results, patients were separated into three biological/pathological (bp) risk groups: a high-risk group (bpHR) including MDD-positive patients with SC/LH pattern<br />a low-risk group (bpLR) including MDD-negative patients without SC/LH pattern<br />and an intermediate-risk group (bpIR) including remaining patients. The 10-year PFS was 40%, 75% and 86% for bpHR, bpIR and bpLR, respectively (p &lt<br />0.0001). These results should be considered in the design of future ALCL trials to tailor individual treatments.
- Subjects :
- MDD
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Multivariate analysis
IMPACT
BONE-MARROW
FEATURES
CHILDREN
long-term follow-up
lcsh:RC254-282
Article
DISEASE
CLASSIFICATION
Childhood Anaplastic Large Cell Lymphoma
03 medical and health sciences
0302 clinical medicine
Internal medicine
ADOLESCENTS
medicine
VINBLASTINE
Progression-free survival
Young adult
Pathological
Anaplastic large-cell lymphoma
childhood
Science & Technology
business.industry
Hazard ratio
CHEMOTHERAPY
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
ALCL
030104 developmental biology
030220 oncology & carcinogenesis
Minimal Disseminated Disease
NON-HODGKIN-LYMPHOMA
business
Life Sciences & Biomedicine
Subjects
Details
- ISSN :
- 20726694
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Cancers
- Accession number :
- edsair.doi.dedup.....3c2d019eefb2e1442f19e4074f3d27e5